"10.1371_journal.pone.0084648","plos one","2013-12-19T00:00:00Z","Lindsay K Ryland; Ushma A Doshi; Sriram S Shanmugavelandy; Todd E Fox; Cesar Aliaga; Kathleen Broeg; Kendall Thomas Baab; Megan Young; Osman Khan; Jeremy K Haakenson; Nancy Ruth Jarbadan; Jason Liao; Hong-Gang Wang; David J Feith; Thomas P Loughran Jr; Xin Liu; Mark Kester","Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America; Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania, United States of America; Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, United States of America","Conceived and designed the experiments: LKR UAD TPL XL MK. Performed the experiments: LKR UAD SSS TEF KB JKH. Analyzed the data: LKR UAD TEF CA NRJ JL HGW TPL XL MK. Contributed reagents/materials/analysis tools: KTB MY OK DJF. Wrote the manuscript: LKR UAD TPL MK.","The authors have read the journals policy and have the following conflicts: Mark Kester, Penn State Research Foundation (PSRF), has licensed ceramide nanoliposomes to Keystone Nano, Inc. PSRF has previously licensed other ceramide nanotechnologies to Keystone Nano, Inc. Mark Kester is Chief Medical Officer of Keystone Nano, Inc, State College, PA. The remaining authors declare no competing financial interests. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Lindsay K Ryland","LKR",17,TRUE,5,6,10,4,TRUE,TRUE,FALSE,0,NA,FALSE
